Close Menu

Breaking News

In a response to the UK CMA's findings that the PacBio deal would lessen competition, Illumina said it would be open to licensing some IP to Oxford Nanopore.

Under a collaboration agreement, the firms plan to put together Agilent's SLIMS laboratory information system and MGI's DNBSeq series of sequencing platforms.

This report contains a quantitative, evidence-based scoring framework to help guide the evaluation of constitutional CNVs across clinical labs.

Centogene's data repository includes rare disease patient data including clinical information, health records, and a range of -omics data.

The Seattle-based immune cell sequencing firm saw sequencing revenues grow 38 percent while development revenues rose 65 percent.

HTG terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments.

Exact argues that JHU has no basis to demand any royalties on sales of Cologuard because the test doesn't use any patents the university licensed to the company.

A single-cell transcriptome study found increased numbers of cytotoxic CD4 T cells, which could be an adaptation to the later stages of aging.

Northern California healthcare system NorthBay Healthcare will evaluate the platform's ability to improve the routine use of genetic testing.

Based on mouse and human data, researchers focused on hypermethylated genes in blood samples from individuals with colorectal cancer and gut dysbiosis.

Due to a ransom cyberattack on its information technology systems, the firm reported full revenue but only preliminary earnings estimates.

The company said it will use the funds to support development of its structure for lossless ion manipulation (SLIM) ion mobility separations technology.

The approval of its Omics Core assay for tumor-normal mutational profiling opens the door for payor reimbursement, which is key to reaching profitability, NantHealth said.

The assay, which received premarket approval last year, detects 14 high-risk HPV types and individually identifies and reports HPV genotypes 16, 18, and 45.

The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.

The system uses chemical epigenetic modifiers to activate the expression of target genes by recruiting an endogenous chromatin-activating machinery.

Last week, GenomeWeb's readers were most interested in Thermo Fisher Scientific's launch of a new sequencing system called the Ion Torrent Genexus.

The company said revenues declined primarily as a result of adjustments in accounts receivable, payor mix, and the timing of test kit collections.

Panelists at the NSGC annual meeting said artificial intelligence approaches like chatbots could complement traditional genetic counseling approaches.

The deal includes Expedeon's core proteomics business, as well as its immunology-focused subsidiaries Innova Biosciences and TGR Biosciences.

The acquisition, slated to close in the coming days, will give Invitae access to Clear Genetics' chatbot Gia, or Genetic Information Assistant.

UK-based Abcam has also taken an undisclosed equity stake in BrickBio, located in Boston, and will work with the company to further develop its platform.

The test is the second infectious disease assay from Bioneer to be CE marked, and the South Korean company has a third test in the pipeline.

Pages

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.